Short answer
RHYTHM PHARMACEUTICALS, INC. (RYTM) filed an 8-K current report with the SEC on February 26, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q4/FY 2025 earnings results disclosed via press release dated February 26, 2026: full financials in Exhibit 99.1.
RHYTHM PHARMACEUTICALS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q4/FY 2025 earnings results disclosed via press release dated February 26, 2026: full financials in Exhibit 99.1
- CFO Hunter C. Smith signed the filing, indicating standard authorized release of financial results
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other RHYTHM PHARMACEUTICALS, INC. 8-K filings
Get the next RYTM 8-K as it lands
Follow RYTM for push alerts, or ask the research agent what this filing means.